Clinical trials: Chronic Idiopathic Constipation
Constipation, Chronic Idiopathic Constipation
BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
The objective of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus placebo in constipated adults.
- Conditions
- Constipation, Chronic Idiopathic Constipation, CIC
- Trial name
- NCT02819297
- Testing
- BLI400 Laxative
- Where
- 51 sites in United States
- Volunteers
- 1,020 people
- Sponsor
- Braintree Laboratories
Chronic Idiopathic Constipation
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to < 18 years diagnosed with Chronic Idiopathic Constipation.
- Trial name
- NCT03120520
- Testing
- Plecanatide
- Where
- 36 sites in United States
- Volunteers
- 124 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT01919697
- Testing
- Plecanatide
- Where
- 220 sites in United States, Canada
- Volunteers
- 2,370 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Lubiprostone for Chronic Idiopathic Constipation Treatment
The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02729909
- Testing
- Lubiprostone
- Where
- 10 sites in Mexico
- Volunteers
- 211 people
- Sponsor
- Takeda
Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
- Trial name
- CIC (NCT02122471)
- Testing
- Plecanatide
- Where
- 167 sites in United States
- Volunteers
- 1,410 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic…
- Trial name
- NCT01429987
- Testing
- plecanatide
- Where
- 121 sites in United States
- Volunteers
- 951 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation, Chronic Constipation
Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation
The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with chronic idiopathic constipation.
- Trial name
- ACCESS (NCT01007123)
- Testing
- A3309
- Where
- 44 sites in United States
- Volunteers
- 190 people
- Sponsor
- Albireo
Constipation, Chronic Idiopathic Constipation
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation is a common gastrointestinal motility disorder that is often chronic, negatively affects patients' daily lives. Constipation occurs when bowel movements become difficult or less frequent.This study is being done to…
- Conditions
- Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
- Trial name
- NCT03054506
- Testing
- CSP01, Carboxymethylcellulose (CMC)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility.
- Trial name
- NCT05652205
- Testing
- Linaclotide
- Where
- 48 sites in United States, Bulgaria and 2 more
- Volunteers
- 123 people
- Sponsor
- AbbVie
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)
The was performed to assess the safety and efficacy of the vibrant capsule vs. placebo for the treatment of subjects with functional Constipation.
- Trial name
- CIC (NCT04458675)
- Testing
- Vibrant capsule
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation.
- Trial name
- NCT01993875
- Testing
- Lubiprostone
- Where
- 11 sites in United States
- Volunteers
- 164 people
- Sponsor
- Mallinckrodt
Chronic Idiopathic Constipation
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT03097861
- Testing
- Lubiprostone
- Where
- 67 sites in United States
- Volunteers
- 552 people
- Sponsor
- Sucampo Pharma Americas, LLC
Chronic Idiopathic Constipation
Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
The purpose of this study is to determine if lubiprostone may change the rate of movement of food and activities in the stomach and intestines in subjects whose gastrointestinal (GI) tract is slower due to constipation.
- Trial name
- NCT01469819
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The CIC3 Study)
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
- Trial name
- NCT01982240
- Testing
- Plecanatide, Bisacodyl
- Where
- 189 sites in United States, Canada
- Volunteers
- 1,394 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
The study is a prospective, randomized, multicenter, adaptive design, double blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs.
- Trial name
- Vibrant (NCT03879239)
- Testing
- Vibrating capsule
- Where
- 8 sites in United States
- Volunteers
- 349 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Efficacy of Linaclotide to Senna for CIC
In this prospective, randomized, double blind study, the aim is to determine the efficacy of Linaclotide in relation to Senna in relieving the symptoms of chronic idiopathic constipation (CIC).
- Trial name
- NCT02239510
- Testing
- Senna, Linzess
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- TriHealth Inc.
Constipation
Lubiprostone for the Treatment of Chronic Idiopathic Constipation
The purpose of this study is to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02651155
- Testing
- Lubiprostone
- Where
- 12 sites in Russia
- Volunteers
- 204 people
- Sponsor
- Takeda
Chronic Idiopathic Constipation
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
- Trial name
- NCT01827592
- Testing
- Elobixibat 10 mg, Elobixibat 5 mg
- Where
- 94 sites in United States, Belgium and 8 more
- Volunteers
- 376 people
- Sponsor
- Ferring Pharmaceuticals
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs).
- Trial name
- NCT02590432
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories